Louise Abildgaard Steffensen
Leo Pharma (Denmark)(DK)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Urticaria and Related Conditions, Food Allergy and Anaphylaxis Research, Allergic Rhinitis and Sensitization
Most-Cited Works
- → Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*(2020)563 cited
- → Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years(2024)46 cited
- → Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials(2023)28 cited
- → Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)(2022)15 cited
- → Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis(2024)14 cited
- → Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2(2021)2 cited
- → Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities(2024)1 cited
- → Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis(2020)1 cited
- → 548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities(2024)1 cited
- → 552 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis(2024)